Mangaluru: Colourful kites paint the sky at Panambur beach

Bengaluru, Jan 19: Australia has conferred its highest civilian honour, the Order of Australia honour, on Biocon founder Kiran Mazumdar-Shaw for her contribution towards advancing the country's relationship with India.

Australia's High Commissioner to India Harinder Sidhu invested Mazumdar-Shaw as an Honorary Member within the Order of Australia (AM) in the General Division at a ceremony in Bengaluru on Friday, the Australian High Commission said in a statement.

An alumnus of Federation University Australia, Mazumdar-Shaw is the founder of Biocon, one of India's largest bio-pharmaceutical companies.

She contributes immensely to promoting women in STEM through the joint research programmes developed between Biocon and Deakin University, Australia, as part of her deep and long-standing commitment to gender equality, the statement said.

Mazumdar-Shaw - an Australian Global Alumni Ambassador - is also recognised for her sustained and significant contribution to industry academia collaboration between Australia and India, it said.

The ceremony was attended by representatives from Indian and Australian business, the diplomatic corps, and family, friends and peers of Mazumdar-Shaw, the statement said.

Speaking at the event, Sidhu said, "Dr Mazumdar-Shaw is a tireless champion of the commercial, educational, and people-to-people links between our two countries, and this award recognises her commitment to progressing the Australia-India partnership."

Honorary appointments in the Order of Australia are made to foreign nationals who have made an outstanding contribution to Australia or humanity at large.

Mazumdar-Shaw is the fourth Indian citizen to be awarded Australia's highest civilian honour.

This follows the conferment of superstar batsman Sachin Tendulkar in 2012, Former Attorney General of India Soli Jehangir Sorabjee in 2006, and Mother Teresa of Kolkata (Agnes Gonxha Bojaxhiu) in 1982.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.